Sabra Healthcare REIT (SBRA)
(Delayed Data from NSDQ)
$18.36 USD
-0.64 (-3.37%)
Updated Sep 19, 2024 04:00 PM ET
After-Market: $18.37 +0.01 (0.05%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth A Momentum D VGM
Income Statements
Fiscal Year end for Sabra Healthcare REIT, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 648 | 625 | 570 | 599 | 662 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 648 | 625 | 570 | 599 | 662 |
Selling & Adminstrative & Depr. & Amort Expenses | 440 | 484 | 368 | 347 | 444 |
Income After Depreciation & Amortization | 207 | 141 | 201 | 252 | 218 |
Non-Operating Income | -76 | -14 | -22 | 4 | -12 |
Interest Expense | 113 | 105 | 99 | 100 | 127 |
Pretax Income | 19 | 22 | 81 | 156 | 79 |
Income Taxes | 2 | 1 | 2 | 1 | 3 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | -3 | -98 | -192 | -17 | -7 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | 14 | -78 | -113 | 138 | 69 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | 14 | -78 | -113 | 138 | 69 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | 390 | 328 | 380 | 428 | 399 |
Depreciation & Amortization (Cash Flow) | 183 | 188 | 179 | 177 | 182 |
Income After Depreciation & Amortization | 207 | 141 | 201 | 252 | 218 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 232.79 | 230.95 | 219.07 | 207.25 | 188.13 |
Diluted EPS Before Non-Recurring Items | 0.06 | -0.34 | -0.52 | 0.67 | 0.37 |
Diluted Net EPS (GAAP) | 0.06 | -0.34 | -0.52 | 0.67 | 0.37 |
Fiscal Year end for Sabra Healthcare REIT, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 176.14 | 166.75 | 163.40 | 161.63 | 161.17 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 176.14 | 166.75 | 163.40 | 161.63 | 161.17 |
SG&A, R&D, and Dept/Amort Expenses | 124.35 | 111.79 | 116.35 | 103.15 | 102.84 |
Income After SG&A, R&D, and Dept/Amort Expenses | 51.79 | 54.96 | 47.05 | 58.48 | 58.33 |
Non-Operating Income | 1.85 | 0.76 | -0.70 | -44.32 | -7.83 |
Interest Expense | 29.31 | 28.41 | 27.94 | 28.16 | 28.33 |
Pretax Income | 24.33 | 27.30 | 18.41 | -14.00 | 22.17 |
Income Taxes | 0.44 | 0.45 | 0.49 | 0.46 | 0.33 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.08 | -0.60 | -0.76 | -0.65 | -0.65 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | 23.98 | 26.25 | 17.16 | -15.10 | 21.19 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | 23.98 | 26.25 | 17.16 | -15.10 | 21.19 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 233.75 | 233.37 | 233.20 | 231.23 | 232.25 |
Diluted EPS Before Non-Recurring Items | 0.10 | 0.11 | 0.07 | -0.07 | 0.09 |
Diluted Net EPS (GAAP) | 0.10 | 0.11 | 0.08 | -0.07 | 0.09 |